Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20082425 | 0.82 | KDM4E (0.47) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20216127 | 0.80 | SOD1 (0.40) | LMNASLC6A4GRM2 | |
| SCHEMBL13498029 | 0.76 | KDM4E (0.46) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL19291432 | 0.75 | GRIN1 (0.45) | KDM4ETSHRALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL19291606 | 0.75 | GRIN1 (0.45) | KDM4ETSHRALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4854291 | 0.73 | KDM4E (0.62) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL19291456 | 0.72 | PPARA (0.40) | — | |
| SCHEMBL20647155 | 0.71 | KDM4E (0.60) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20216199 | 0.70 | HRH3 (0.43) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13498042 | 0.70 | KDM4E (0.46) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | KDM4E 866/4885TSHR 3159/4885ALDH1A1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.